Rational Design of Potent and Highly Selective FGFR1 Irreversible Inhibitors Guided by Molecular Dynamics Simulations
- 23 October 2026
- journal article
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 69 (21) , 26135-26162
Abstract
Molecular dynamics (MD) simulations revealed distinct P-loop conformational differences in the ATP-binding domain between FGFR1 and other FGFR subtypes. A conformation-restricted linker optimization strategy was applied to identify a potent and selective irreversible FGFR1 inhibitor (compound 24). MD models demonstrated that the covalent warhead of compound 24 retained an optimal distance and orientation toward the P-loop cysteine of FGFR1, facilitating efficient Michael addition. After covalent conjugation, compound 24 interacted with the hinge region and precisely matched the unique FGFR1 conformation. Its robust antitumor activity was validated in cellular, CDX, and PDX models by suppressing FGFR1-dependent tumor growth, providing a novel strategy for subtype-selective FGFR1 inhibitor development.Keywords
Funding Information
- Fundamental Research Funds for the Central Universities (735-63253255)
- National Natural Science Foundation of China (824B2114)
- National Natural Science Foundation of China (82470167)
- Natural Science Foundation of Tianjin Municipality (24JCYBJC01990)
- Natural Science Foundation of Tianjin Municipality (25JCONJC01230)
- Tianjin Municipal Health Commission (TJYXZDXK-3-003A-5)
- China Postdoctoral Science Foundation (2026T029TJ)
- Tianjin Key Medical Discipline Construction Project (TJYXZDXK-3-009B)
This publication has 36 references indexed in Scilit:
- Small-molecule FGFR-targeted medicinal chemistry: Advances since 2020 and future perspectivesEuropean Journal of Medicinal Chemistry, 2025
- FGFs/FGFRs and neuroinflammatory diseases: mechanism, drug therapies and delivery systemsJournal of Advanced Research, 2025
- Discovery and characterization of novel FGFR1 inhibitors in triple-negative breast cancer via hybrid virtual screening and molecular dynamics simulationsBioorganic Chemistry, 2024
- A novel FGFR1 inhibitor CYY292 suppresses tumor progression, invasion, and metastasis of glioblastoma by inhibiting the Akt/GSK3β/snail signaling axisGenes & Diseases, 2024
- Design, synthesis and evaluation of novel pyrimidinylaminothiophene derivatives as FGFR1 inhibitors against human glioblastoma multiformeEuropean Journal of Medicinal Chemistry, 2023
- Bemarituzumab in patients with FGFR2b-selected gastric or gastro-oesophageal junction adenocarcinoma (FIGHT): a randomised, double-blind, placebo-controlled, phase 2 studyThe Lancet Oncology, 2022
- Infigratinib (BGJ398) in previously treated patients with advanced or metastatic cholangiocarcinoma with FGFR2 fusions or rearrangements: mature results from a multicentre, open-label, single-arm, phase 2 studyThe Lancet Gastroenterology & Hepatology, 2021
- Pemigatinib for previously treated, locally advanced or metastatic cholangiocarcinoma: a multicentre, open-label, phase 2 studyThe Lancet Oncology, 2020
- First-in-Human Phase I Study of Aprutumab Ixadotin, a Fibroblast Growth Factor Receptor 2 Antibody–Drug Conjugate (BAY 1187982) in Patients with Advanced CancerTargeted Oncology, 2019
- Discovery and identification of new non-ATP competitive FGFR1 inhibitors with therapeutic potential on non-small-cell lung cancerCancer Letters, 2014